Aratana Therapeutics Stock Company Profile
Information
11400 Tomahawk Creek Parkway
Leawood KS 66211
913-353-1000
www.aratana.com
Description
Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of biopharmaceutical products for the companion animals worldwide. Its product portfolio includes various therapeutic candidates consisting of small molecule pharmaceuticals and large molecule biologics that target various opportunities in serious medical conditions in pets. The company develops AT-001, a prostaglandin E2 EP4 receptor antagonist, to treat osteoarthritis pain and inflammation in dogs, as well as degenerative joint disease in cats; AT-002, a ghrelin agonist for appetite stimulation in dogs, as well as for weight gain in cats and dogs; AT-003, a bupivacaine liposome injectable suspension for the treatment of post-operative pain in dogs and cats; AT-004, a caninized monoclonal antibody for the treatment of B-cell lymphoma in dogs; and AT-005, a caninized monoclonal antibody for the treatment of T-cell lymphoma in dogs. It also develops AT-014, a novel her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma and other cancers in dogs; AT-016 that provides long-term relief of pain and disability caused by osteoarthritis through regeneration of joint damage in dogs; and AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs. In addition, the company develops products for the treatment of lymphoma and other cancers in multiple species, canine allergy, feline calicivirus, feline herpesvirus, feline immunodeficiency virus, and periodontal disease. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.